BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29100957)

  • 21. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
    Karp JE; Lancet JE
    Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ras family signaling: therapeutic targeting.
    Cox AD; Der CJ
    Cancer Biol Ther; 2002; 1(6):599-606. PubMed ID: 12642680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein farnesyltransferase inhibitors.
    Ayral-Kaloustian S; Salaski EJ
    Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status of clinical trials of farnesyltransferase inhibitors.
    Karp JE; Kaufmann SH; Adjei AA; Lancet JE; Wright JJ; End DW
    Curr Opin Oncol; 2001 Nov; 13(6):470-6. PubMed ID: 11673687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.
    Pan J; Yeung SC
    Cancer Res; 2005 Oct; 65(20):9109-12. PubMed ID: 16230362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Nat Rev Drug Discov; 2007 Jul; 6(7):541-55. PubMed ID: 17585331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.
    Adjei AA
    Lung Cancer; 2003 Aug; 41 Suppl 1():S55-62. PubMed ID: 12867063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
    Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
    Curr Med Chem; 2013; 20(38):4888-923. PubMed ID: 24059235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: substrate-based design, conformational constraint and biological activity.
    Dinsmore CJ; Bell IM
    Curr Top Med Chem; 2003; 3(10):1075-93. PubMed ID: 12769709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
    Prendergast GC; Oliff A
    Semin Cancer Biol; 2000 Dec; 10(6):443-52. PubMed ID: 11170866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of farnesyltransferase: a rational approach to treat cancer?
    Puntambekar DS; Giridhar R; Yadav MR
    J Enzyme Inhib Med Chem; 2007 Apr; 22(2):127-40. PubMed ID: 17518338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Farnesyltransferase inhibitors.
    Sebti SM; Adjei AA
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):28-39. PubMed ID: 14981578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group.
    Tanaka A; Radwan MO; Hamasaki A; Ejima A; Obata E; Koga R; Tateishi H; Okamoto Y; Fujita M; Nakao M; Umezawa K; Tamanoi F; Otsuka M
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3862-3866. PubMed ID: 28666734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
    Helbig G; HoĊ‚owiecki J
    Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
    Gotlib J
    Curr Hematol Rep; 2005 Jan; 4(1):77-84. PubMed ID: 15610664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects.
    Prendergast GC
    Curr Opin Cell Biol; 2000 Apr; 12(2):166-73. PubMed ID: 10712917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Farnesyltransferase inhibitors: targeting the molecular basis of cancer.
    Oliff A
    Biochim Biophys Acta; 1999 May; 1423(3):C19-30. PubMed ID: 10382537
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical activity of tipifarnib in hematologic malignancies.
    Jabbour E; Kantarjian H; Cortes J
    Expert Opin Investig Drugs; 2007 Mar; 16(3):381-92. PubMed ID: 17302532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Farnesyltransferase inhibitors as radiation sensitizers.
    McKenna WG; Muschel RJ; Gupta AK; Hahn SM; Bernhard EJ
    Semin Radiat Oncol; 2002 Jul; 12(3 Suppl 2):27-32. PubMed ID: 12174342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Farnesyltransferase inihibitors in hematologic malignancies.
    Harousseau JL
    Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.